Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation

International Journal of Rheumatic Diseases

Volumn 20, Issue 7, 2017, Pages 859-869

  Chen, Le Feng ^a   Mo, Ying Qian ^a   Jing, Jun ^a   Ma, Jian Da ^a   Zheng, Dong Hui ^a   Dai, Lie ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

hepatitis B virus; reactivation; rheumatoid arthritis; tocilizumab

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; HEPATITIS B ANTIBODY; TOCILIZUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; VIRUS DNA;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK FACTOR; SHORT COURSE THERAPY; TREATMENT OUTCOME; VIRUS REACTIVATION; BLOOD; DRUG ADMINISTRATION; GENETICS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; LIVER FUNCTION TEST; MIDDLE AGED; PATHOGENICITY; TIME FACTOR; VIRUS ACTIVATION; VIRUS LOAD;

ADMINISTRATION, INTRAVENOUS; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOMARKERS; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B VIRUS; HUMANS; IMMUNOCOMPROMISED HOST; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS ACTIVATION;

EID: 85012054761     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.13010     Document Type: Article

References (31)

1. Wands JR, Chura CM, Roll FJ, Maddrey WC (1975) Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 68, 105–12.
2. Onozawa M, Hashino S, Izumiyama K et al. (2005) Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 79, 616–9.
3. Nordbø SA, Skaug K, Holter E, Waage A, Brinch L (2000) Reactivation of hepatitis B virus infection in an anti-HBc and anti-HBs positive patient after allogeneic bone marrow transplantation. Eur J Haematol 65, 86–7.
4. Koo YX, Tay M, Teh YE et al. (2011) Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol 90, 1219–23.
5. Liaw YF, Chu CM (2009) Hepatitis B virus infection. Lancet 373, 582–92.
6. Lozano R, Naghavi M, Foreman K et al. (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095–128.
7. Trépo C, Chan HL, Lok A (2014) Hepatitis B virus infection. Lancet 384, 2053–63.
8. Zou CJ, Zhu LJ, Li YH et al. (2013) The association between hepatitis B virus infection and disease activity, synovitis, or joint destruction in rheumatoid arthritis. Clin Rheumatol 32, 787–95.
9. Liang X, Bi S, Yang W et al. (2009) Epidemiological serosurvey of hepatitis B in China–declining HBV prevalence due to hepatitis B vaccination. Vaccine 27, 6550–7.
10. Mo YQ, Liang AQ, Ma JD et al. (2014) Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice. BMC Musculoskelet Disord 15, 449.
11. Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F et al. (2011) Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 90, 359–71.
12. Ye H, Zhang XW, Mu R et al. (2014) Anti-TNF therapy in patients with HBV infection–analysis of 87 patients with inflammatory arthritis. Clin Rheumatol 33, 119–23.
13. Lan JL, Chen YM, Hsieh TY et al. (2011) Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 70, 1719–25.
14. Lu S, Xu Y, Mu Q et al. (2015) The risk of hepatitis B virus reactivation and the role of antiviral prophylaxis in hepatitis B surface antigen negative/hepatitis B core antibody positive patients with diffuse large B-cell lymphoma receiving rituximab based chemotherapy. Leuk Lymphoma 56, 1027–32.
15. Genovese MC, McKay JD, Nasonov EL et al. (2008) Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58, 2968–80.
16. Jones G, Sebba A, Gu J et al. (2010) Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 69, 88–96.
17. Shi Q, Zhao Y, Bao CD et al. (2013) The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial. Zhonghua Nei Ke Za Zhi 52, 323–9.
18. Hoofnagle JH (2009) Reactivation of hepatitis B. Hepatology 49 (5 Suppl.), S156–65.
19. Perrillo RP, Gish R, Falck-Ytter YT (2015) American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148, 221–44.e3.
20. Hwang JP, Lok AS (2014) Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol 11, 209–19.
21. Singh JA, Furst DE, Bharat A et al. (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64, 625–39.
22. Singh JA, Saag KG, Bridges SL Jr et al. (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 68 (1), 1–25.
23. Nagashima T, Minota S (2008) Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B. Rheumatology (Oxford) 47, 1838–40.
24. Tsuboi H, Tsujii A, Nampei A et al. (2011) A patient with rheumatoid arthritis treated with tocilizumab together with lamivudine prophylaxis after remission of infliximab reactivated hepatitis B. Mod Rheumatol 21, 701–5.
25. Kishida D, Okuda Y, Onishi M et al. (2011) Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis. Mod Rheumatol 21, 215–8.
26. Reddy KR, Beavers KL, Hammond SP et al. (2015) American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148, 215–9.
27. Hösel M, Quasdorff M, Wiegmann K et al. (2009) Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 50, 1773–82.
28. Kuo TM, Hu CP, Chen YL et al. (2009) HBV replication is significantly reduced by IL-6. J Biomed Sci 16, 41.
29. Stoop JN, van der Molen RG, Kuipers EJ et al. (2007) Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B. Virology 361 (1), 141–8.
30. Charpin C, Guis S, Colson P et al. (2009) Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther 11, R179.
31. Mitroulis I, Hatzara C, Kandili A, Hadziyannis E, Vassilopoulos D (2013) Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 72, 308–10.